<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.118554</article-id><article-id pub-id-type="publisher-id">ACM-44846</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210800000_73914641.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  欧米伽-3脂肪酸对轻度认知障碍患者的蒙特利尔认知评估量表评分的影响
  Effect of Omega-3 Fatty Acids on the Score of Montreal Cognitive Assessment Scale in Patients with Mild Cognitive Impairment
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>潇潇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>田</surname><given-names>飞</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>辰辉</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>平</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff4"><addr-line>青岛市精神卫生中心，山东 青岛</addr-line></aff><aff id="aff3"><addr-line>青岛大学，山东 青岛；青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff2"><addr-line>青岛大学，山东 青岛；青岛市精神卫生中心，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>08</month><year>2021</year></pub-date><volume>11</volume><issue>08</issue><fpage>3772</fpage><lpage>3777</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  目的：探讨欧米伽-3脂肪酸对轻度认知障碍患者的蒙特利尔认知评估量表评分的影响。方法：将60例轻度认知障碍(MCI)患者随机分配到欧米伽-3脂肪酸鱼油组(每日包含720 mg EPA和480 mg DHA)和安慰剂组，使用蒙特利尔认知评估量表(MoCA)对MCI进行认知功能测评；用气象色谱仪发分析血浆EPA及DHA含量。结果：干预8周后，鱼油组8周后MoCA评分[23.5 (21.50, 25.25)]较基线评分[23 (20.25, 24)]无统计学差异(P = 0.256)，但量表评分有提高。安慰剂组8周较基线评分无改善。结论：欧米伽-3多不饱和脂肪酸鱼油胶囊可以改善MCI患者的蒙特利尔认知评估量表评分，进一步的研究应进行更大的样本量，更大的欧米伽–脂肪酸剂量和更长的随访时间来进一步明确结论。
   Objective: To investigate the effect of omega-3 fatty acids on the score of Montreal cognitive assessment scale in patients with mild cognitive impairment. Methods: 60 patients with mild cognitive impairment (MCI) were randomly assigned to omega-3 fatty acid fish oil group (including 720 mg EPA and 480 mg DHA daily) and placebo group. The cognitive function of MCI was assessed by Montreal Cognitive Assessment scale (MoCA), and the contents of plasma EPA and DHA were analyzed by meteorological chromatograph. Results: After 8 weeks of intervention, there was no significant difference in the MoCA score between the fish oil group and the baseline score [23.5 (21.50, 25.25)] vs [23 (20.25, 24)], (P = 0.256), but the score of the scale was improved. There was no improvement in the placebo group compared with the baseline score at 8 weeks. Conclusion: Omega-3 polyunsaturated fatty acid can improve the score of Montreal cognitive assessment scale in patients with MCI. Further studies should be conducted with larger sample size, larger dose of omega-fatty acid and longer follow-up time to further confirm the conclusion.
 
</p></abstract><kwd-group><kwd>欧米伽-3脂肪酸，轻度认知障碍，蒙特利尔认知评估量表，认知功能, Omega-3 Fatty Acids</kwd><kwd> Mild Cognitive Impairment</kwd><kwd> Montreal Cognitive Assessment Scale</kwd><kwd> Cognitive Function</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨欧米伽-3脂肪酸对轻度认知障碍患者的蒙特利尔认知评估量表评分的影响。方法：将60例轻度认知障碍(MCI)患者随机分配到欧米伽-3脂肪酸鱼油组(每日包含720 mg EPA和480 mg DHA)和安慰剂组，使用蒙特利尔认知评估量表(MoCA)对MCI进行认知功能测评；用气象色谱仪发分析血浆EPA及DHA含量。结果：干预8周后，鱼油组8周后MoCA评分[23.5 (21.50, 25.25)]较基线评分[23 (20.25, 24)]无统计学差异(P = 0.256)，但量表评分有提高。安慰剂组8周较基线评分无改善。结论：欧米伽-3多不饱和脂肪酸鱼油胶囊可以改善MCI患者的蒙特利尔认知评估量表评分，进一步的研究应进行更大的样本量，更大的欧米伽–脂肪酸剂量和更长的随访时间来进一步明确结论。</p></sec><sec id="s2"><title>关键词</title><p>欧米伽-3脂肪酸，轻度认知障碍，蒙特利尔认知评估量表，认知功能</p></sec><sec id="s3"><title>Effect of Omega-3 Fatty Acids on the Score of Montreal Cognitive Assessment Scale in Patients with Mild Cognitive Impairment<sup> </sup></title><p>Xiaoxiao Wang<sup>1,2</sup>, Fei Tian<sup>1,3</sup>, Chenhui Sun<sup>2</sup>, Ping Sun<sup>2</sup></p><p><sup>1</sup>Qingdao University, Qingdao Shandong</p><p><sup>2</sup>Qingdao Mental Health Center, Qingdao Shandong</p><p><sup>3</sup>Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/71-1572510x4_hanspub.png?20210830082310665" /></p><p>Received: Jul. 26<sup>th</sup>, 2021; accepted: Aug. 19<sup>th</sup>, 2021; published: Aug. 27<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/71-1572510x5_hanspub.png?20210830082310665" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To investigate the effect of omega-3 fatty acids on the score of Montreal cognitive assessment scale in patients with mild cognitive impairment. Methods: 60 patients with mild cognitive impairment (MCI) were randomly assigned to omega-3 fatty acid fish oil group (including 720 mg EPA and 480 mg DHA daily) and placebo group. The cognitive function of MCI was assessed by Montreal Cognitive Assessment scale (MoCA), and the contents of plasma EPA and DHA were analyzed by meteorological chromatograph. Results: After 8 weeks of intervention, there was no significant difference in the MoCA score between the fish oil group and the baseline score [23.5 (21.50, 25.25)] vs [23 (20.25, 24)], (P = 0.256), but the score of the scale was improved. There was no improvement in the placebo group compared with the baseline score at 8 weeks. Conclusion: Omega-3 polyunsaturated fatty acid can improve the score of Montreal cognitive assessment scale in patients with MCI. Further studies should be conducted with larger sample size, larger dose of omega-fatty acid and longer follow-up time to further confirm the conclusion.</p><p>Keywords:Omega-3 Fatty Acids, Mild Cognitive Impairment, Montreal Cognitive Assessment Scale, Cognitive Function</p><disp-formula id="hanspub.44846-formula27"><graphic xlink:href="//html.hanspub.org/file/71-1572510x6_hanspub.png?20210830082310665"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/71-1572510x7_hanspub.png?20210830082310665" /> <img src="//html.hanspub.org/file/71-1572510x8_hanspub.png?20210830082310665" /></p></sec><sec id="s5"><title>1. 前言</title><p>人口老龄化问题使得轻度认知障碍(Mild Cognitive Impairment, MCI)患者的患病率不断增长，有研究提示全世界的最高患病率42% [<xref ref-type="bibr" rid="hanspub.44846-ref1">1</xref>]，中国的最高患病率为35.9% [<xref ref-type="bibr" rid="hanspub.44846-ref2">2</xref>]，轻度认知障碍是发展为痴呆的前期阶段，及时干预可能延缓发展为痴呆的进程。</p><p>欧米伽-3多不饱和脂肪酸是神经元重要的成分，尤其是二十碳五烯酸(EPA)和二十二碳六烯酸(DHA)，可能对年龄相关的认知功能下降起到保护作用 [<xref ref-type="bibr" rid="hanspub.44846-ref3">3</xref>]。本研究中纳入轻度认知障碍患者60例，进行一项为期8周的临床随机对照实验，采用蒙特利尔认知评估量表测试受试者认知功能，旨在探讨欧米伽-3多不饱和脂肪对度认知障碍患者的蒙特利尔认知评估量表评分的影响。</p></sec><sec id="s6"><title>2. 对象与方法</title><sec id="s6_1"><title>2.1. 对象</title><p>选取2020年10月至2021年5月青岛市精神卫生中心门诊就诊的轻度认知功能障碍患者为受试者。入组标准及排除标准参考中国痴呆与认知障碍诊治指南 [<xref ref-type="bibr" rid="hanspub.44846-ref4">4</xref>] 及以往文献 [<xref ref-type="bibr" rid="hanspub.44846-ref5">5</xref>]：1) 患者或知情者报告，或有经验的临床医生发现认知损伤；2) 患有记忆障碍或其他认知障碍至少3个月的人；3) 受教育程度 ≥ 6年MMSE得分为24~26分；受教育程度 &lt; 6年MMSE得分为20~22分；未受过教育的人MMSE得分为17~19分；4) 保持独立的生活能力；5) 未达到痴呆标准；6) 患者对本项研究知情同意，且签署知情同意书。排除标准：1) 有严重的躯体性疾病或神经系统疾病；2) 对ω-3脂肪酸、鱼类或贝类过敏史；3) 每周吃鱼次数 &gt; 1次或近3个月服用鱼油胶囊；4) 焦虑抑郁等精神疾病所致认知功能损伤。脱落标准：1) 受试者在研究期间改变饮食结构或服用改善认知的药物；2) 受试者因对鱼油胶囊或安慰剂不耐受而出现严重不良反应；3) 受试者因为其他身体因素不能继续参与研究。所有受试者由2名经过专业培训并有3年以上工作经验的精神科医师进行筛选。</p><p>将受试者按照随机数字表法随机分到含有n-3 PUFA鱼油胶囊组(NUTRITION29澳大利亚) (n = 30例)及安慰剂组(n = 30例)。鱼油组轻度认知障碍患者每日服用鱼油2粒，每日1次，共包含720 mg EPA和480 mg DHA。安慰剂组的轻度认知障碍受试者则服用维生素E胶囊，同样的每日1次，每次2粒，安慰剂胶囊在颜色、形状和质地上鱼油胶囊相似。两组受试者对他们服用哪种制剂并不知情。</p><p>本研究受试者均同意，且研究经青岛市精神卫生中心伦理委员会批准。</p></sec><sec id="s6_2"><title>2.2. 量表</title><sec id="s6_2_1"><title>2.2.1. 简易智力状态检查(Mini-Mental State Examination, MMSE)</title><p>MMSE是常用的认知缺损筛选工具之一，共19项，30小项。项目1~5项是时间定向；6~10为地点定向；项目11分3小项，为语言即刻记忆；项目12为5小项，检查注意和计算；项目13分3小项，查短程记忆；项目14分2小项，为物体命名；项目15为语言复述；项目16为阅读理解；项目17为语言理解，分3小项；项目18检测言语表达；项目19为图形描述。回答或操作正确记“1”，错误、拒绝或说不会记“0”，MMSE的主要统计量为所有记“1”的项目的总和，范围为0~30分。本研究中使用MMSE量表对轻度认知障碍人群进行筛选，受教育程度 ≥ 6年MMSE得分为24~26分；受教育程度 &lt; 6年MMSE得分为20~22分；未受过教育的人MMSE得分为17~19分。由2名经过专业培训并有 3 年以上工作经验的精神科医师进行入组人员的筛选。</p></sec><sec id="s6_2_2"><title>2.2.2. 蒙特利尔认知评估量表(Montreal Cognitive Assessment, MoCA)</title><p>蒙特利尔认知评估量表共包括8项认知领域的测试：视空间功能、执行功能、记忆功能、注意力、计算力、抽象思维能力、语言功能、定向力。总分共30分。研究人员将在基线和第8周使用本量表测试受试者认知水平。</p></sec></sec><sec id="s6_3"><title>2.3. 血液学检测</title><p>于基线及第8周采集患者空腹静脉血，用气象色谱依法分析血浆EPA、DHA含量变化，依次来评定患者的依从性，每种脂肪酸以对血浆磷脂酰胆碱中确定的总脂肪酸所占的百分比来表示。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>本研究为两独立样本均数比较，查阅文献 [<xref ref-type="bibr" rid="hanspub.44846-ref6">6</xref>] 了解鱼油组和安慰剂组MMSE的总分(均数 &#177; 标准差)为[(27.18 &#177; 1.80) vs. (24.56 &#177; 4.18)]，设双侧α = 0.05，β = 0.1，查表得Z<sub>α</sub><sub>/2</sub> = 1.96，Z<sub>β</sub> = 1.28，根据两组均</p><p>数比较样本量计算公式 n = [ Z α / 2 + Z β δ / σ ] 2 ∗ ( Q 1 − 1 + Q 2 1 ) 估算每组样本量，考虑样本脱落可能，适当扩大样本</p><p>量，最终纳入研究的样本量为60例。</p><p>应用SPSS26.0统计软件进行分析。数据为正态分布用(x &#177; s)描述，为偏态分布则用M(Q<sub>L</sub>, Q<sub>U</sub>)描述，鱼油组和安慰剂组的基本临床特征比较采用t检验或χ<sup>2</sup>检验，组间各量表评分比较采用独立样本t检验、Kruskal-Wallis H检验，采用Bonferroni校正进行事后多重比较。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 鱼油组和安慰剂组一般人口学及临床资料比较</title><p>鱼油组和安慰剂组在基本临床特征上的差异均无统计学意义，(各项均P &gt; 0.05)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of basic clinical features between fish oil group and placebo group [n (%)/(x &#177; s)</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >条目</th><th align="center" valign="middle" >鱼油组(n = 30)</th><th align="center" valign="middle" >安慰剂组(n = 30)</th><th align="center" valign="middle" >t/χ<sup>2</sup>值</th><th align="center" valign="middle" >P</th></tr></thead><tr><td align="center" valign="middle" >年龄</td><td align="center" valign="middle" >69.20 &#177; 4.89</td><td align="center" valign="middle" >68.50 &#177; 5.51</td><td align="center" valign="middle" >0.521</td><td align="center" valign="middle" >0.604</td></tr><tr><td align="center" valign="middle" >性别</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.148</td><td align="center" valign="middle" >0.284</td></tr><tr><td align="center" valign="middle" >男</td><td align="center" valign="middle" >9 (30)</td><td align="center" valign="middle" >13 (43.3)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >女</td><td align="center" valign="middle" >21 (70)</td><td align="center" valign="middle" >17 (56.7)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >受教育程度</td><td align="center" valign="middle" >5.40 &#177; 2.79</td><td align="center" valign="middle" >5.53 &#177; 2.57</td><td align="center" valign="middle" >−0.193</td><td align="center" valign="middle" >0.848</td></tr><tr><td align="center" valign="middle" >BMI</td><td align="center" valign="middle" >21.44 &#177; 2.06</td><td align="center" valign="middle" >22.40 &#177; 2.92</td><td align="center" valign="middle" >−1.48</td><td align="center" valign="middle" >0.146</td></tr><tr><td align="center" valign="middle" >MMSE</td><td align="center" valign="middle" >24.70 &#177; 2.12</td><td align="center" valign="middle" >25.30 &#177; 1.84</td><td align="center" valign="middle" >−1.171</td><td align="center" valign="middle" >0.247</td></tr></tbody></table></table-wrap><p>表1. 鱼油组与安慰剂组基本临床特征比较[例数(%)/(x &#177; s)]</p></sec><sec id="s7_2"><title>3.2. 鱼油组与安慰剂组服药8周后的蒙特利尔认知评估量表比较</title><p>表2总结了8周补充鱼油胶囊和安慰剂前后蒙特利尔认知评估量表评分，从表中可以看出干预8周后，鱼油组8周后评分[23.5 (21.50, 25.25)]较基线评分[23 (20.25, 24)]无统计学差异(P = 0.256)，但量表评分有提高。安慰剂组8周较基线评分无改善[21 (18, 24)] vs [21 (18, 24)]。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of MoCA between fish oil group and placebo group after 8 week</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >基线</th><th align="center" valign="middle" >第8周</th><th align="center" valign="middle" >Z值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >安慰剂组(n = 30)</td><td align="center" valign="middle" >21.5 (19, 24)</td><td align="center" valign="middle" >21 (18, 24)</td><td align="center" valign="middle" >−0.410</td><td align="center" valign="middle" >0.682</td></tr><tr><td align="center" valign="middle" >鱼油组(n = 30)</td><td align="center" valign="middle" >23 (20.25, 24)</td><td align="center" valign="middle" >23.5 (21.50, 25.25)<sup>*</sup></td><td align="center" valign="middle" >−1.136</td><td align="center" valign="middle" >0.256</td></tr></tbody></table></table-wrap><p>表2. 鱼油组与安慰剂组服药8周后的蒙特利尔认知评估量表比较</p><p><sup>*</sup>与安慰剂组第8周比较，经Kruskal-Wallis H 检验，Bonferroni法校正，P &lt; 0.05。</p></sec><sec id="s7_3"><title>3.3. 鱼油组和安慰剂组两组患者血浆EPA、DHA含量变化</title><p>鱼油组和安慰剂组分别有27例和23例患者采集血样，在基线水平两组患者之间血浆EPA及DHA含量差异无统计学意义，P &gt; 0.05。干预8周后，鱼油组患者血浆EPA含量(1.12 &#177; 0.34)%和DHA含量(1.73 &#177; 0.29)%均明显高于安慰剂组，均P &lt; 0.05。见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Changes of plasma EPA and DHA levels in fish oil group and placebo grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  ></th><th align="center" valign="middle"  rowspan="2"  >基线</th><th align="center" valign="middle"  rowspan="2"  >第8周</th><th align="center" valign="middle"  colspan="3"  >差值95%置信区间</th><th align="center" valign="middle"  rowspan="2"  >P值</th></tr></thead><tr><td align="center" valign="middle" >差值</td><td align="center" valign="middle" >下限</td><td align="center" valign="middle" >上限</td></tr><tr><td align="center" valign="middle"  colspan="7"  >EPA (%)</td></tr><tr><td align="center" valign="middle" >安慰剂组(n = 23)</td><td align="center" valign="middle" >0.83 &#177; 0.35</td><td align="center" valign="middle" >0.81 &#177; 0.36</td><td align="center" valign="middle" >0.019</td><td align="center" valign="middle" >−0.21</td><td align="center" valign="middle" >0.22</td><td align="center" valign="middle" >0.878</td></tr><tr><td align="center" valign="middle" >鱼油组(n = 27)</td><td align="center" valign="middle" >0.81 &#177; 0.11</td><td align="center" valign="middle" >1.12 &#177; 0.34<sup>*</sup></td><td align="center" valign="middle" >−0.30</td><td align="center" valign="middle" >−0.44</td><td align="center" valign="middle" >−0.16</td><td align="center" valign="middle" >&lt;0.0001</td></tr><tr><td align="center" valign="middle"  colspan="5"  >DHA (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >安慰剂组(n = 23)</td><td align="center" valign="middle" >1.62 &#177; 0.24</td><td align="center" valign="middle" >1.44 &#177; 0.27</td><td align="center" valign="middle" >0.17</td><td align="center" valign="middle" >−0.03</td><td align="center" valign="middle" >0.38</td><td align="center" valign="middle" >0.124</td></tr><tr><td align="center" valign="middle" >鱼油组(n = 27)</td><td align="center" valign="middle" >1.52 &#177; 0.25</td><td align="center" valign="middle" >1.73 &#177; 0.29<sup>*</sup></td><td align="center" valign="middle" >−0.20</td><td align="center" valign="middle" >−0.40</td><td align="center" valign="middle" >−0.01</td><td align="center" valign="middle" >0.042</td></tr></tbody></table></table-wrap><p>表3. 鱼油组和安慰剂组两组患者血浆EPA、DHA含量变化</p><p>注：EPA：二十碳五烯酸；DHA：二十二碳六烯酸。<sup>*</sup>与安慰剂组8周比较，P &lt; 0.05。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>轻度认知障碍(MCI)是可能是痴呆的最早阶段，也可能是进行预防痴呆治疗的最佳时机 [<xref ref-type="bibr" rid="hanspub.44846-ref7">7</xref>]。欧米伽-3多不饱和脂肪酸是人体必需的脂肪酸，有研究表明食用富含欧米伽-3多不饱和脂肪酸的鱼油可以降低阿尔茨海默病导致的认知功能下降的风险 [<xref ref-type="bibr" rid="hanspub.44846-ref8">8</xref>]，在本研究使用的认知测评量表是蒙特利尔认知评估量表(MoCA)，在一项专家共识中指出MoCA涵盖的认知领域较简明精神量表(MMSE)广，在识别MCI时有较高的敏感度(80%~100%)和特异度(50%~76%) [<xref ref-type="bibr" rid="hanspub.44846-ref4">4</xref>]。我们进行了一项为期8周的随机对照研究，旨在探讨服用欧米伽-3多不饱和脂肪酸8周后是否可以改善MCI患者的蒙特利尔认知评估量表(MoCA)评分。本研究的初步结果显示，服用欧米伽-3脂肪酸胶囊耐受性好，未显示出严重的不良反应，仅少数受试者诉吞咽困难。</p><p>在本研究中，8周后鱼油组MoCA评分较安慰剂组虽然无统计意义上的差异，但是评分有改善。国内有学者进项了一项为期6个月双盲随机对照实验，发现服用含有480 mg DHA和720 mg EPA的欧米伽-3不饱和脂肪酸对于60岁以上的MCI患者可以改善基本认知能力倾向测验(BCAT)总分、知觉速度、空间表象效率和工作记忆 [<xref ref-type="bibr" rid="hanspub.44846-ref9">9</xref>]。国外也有学者进行了相应的研究，在Lee等人的研究中发现，连续12个月补充含有430 mg DHA和150 mg EPA鱼油胶囊，在短时记忆、工作记忆、即刻言语记忆和延迟回忆能力方面均有很好的改善 [<xref ref-type="bibr" rid="hanspub.44846-ref10">10</xref>]。Chiu和Sinn的结果也显示服用欧米伽-3多不饱和脂肪酸会改善MCI的认知，有利于MCI患者的心理健康，可能会降低MCI发展为痴呆的风险 [<xref ref-type="bibr" rid="hanspub.44846-ref11">11</xref>] [<xref ref-type="bibr" rid="hanspub.44846-ref12">12</xref>]。既往的Meta分析结果显示n-3 PUFA可以改善老年人MMSE评分，降低认知能力下降的速度 [<xref ref-type="bibr" rid="hanspub.44846-ref13">13</xref>]。</p><p>目前因为人们对轻度认知障碍患者症状的不重视，经常被患者本人及家属所忽视，并且误认为是年龄导致的正常衰退而往往延误病情。虽然目前改善认知功能的药物很多，但是截止目前还没有FDA批准的治疗MCI认知症状的药物。在没有统一防治方案的情况下，积极预防MCI，延缓MCI转化为痴呆成为重中之重。欧米伽-3不饱和脂肪酸改善认知的机制目前认为和其抗炎作用 [<xref ref-type="bibr" rid="hanspub.44846-ref14">14</xref>] 和增加海马神经元发生 [<xref ref-type="bibr" rid="hanspub.44846-ref15">15</xref>] 有关。在我们这项随机对照研究中可以观察到8周内每日补充包含720 mg EPA和480 mg DHA的欧米伽-3多不饱和脂肪酸鱼油胶囊可以改善MCI患者的蒙特利尔认知评估量表评分，这给我们今后在饮食营养结构方面预防或延缓MCI发展为痴呆提供了参考，并且欧米伽-3不饱和脂肪酸副反应轻微，以往的研究结果也提示欧米伽-3不饱和脂肪酸可以降低老年人血脂、胆固醇以及改善视力情况等优势 [<xref ref-type="bibr" rid="hanspub.44846-ref16">16</xref>]，而这些特点易于被老年人所接受。</p><p>但是结果也受限于研究中的不足：1) 本研究为单盲随机对照研究，不能排除研究人员主观因素造成的偏倚；2) 本研究中使用的非参数检验方法，可能会遗漏部分数据信息；应进行更大的样本量，更大的剂量和更长的随访时间来进一步明确结论。</p></sec><sec id="s9"><title>文章引用</title><p>王潇潇,田 飞,孙辰辉,孙 平. 欧米伽-3脂肪酸对轻度认知障碍患者的蒙特利尔认知评估量表评分的影响Effect of Omega-3 Fatty Acids on the Score of Montreal Cognitive Assessment Scale in Patients with Mild Cognitive Impairment[J]. 临床医学进展, 2021, 11(08): 3772-3777. https://doi.org/10.12677/ACM.2021.118554</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.44846-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ward, A., Arrighi, H.M., Michels, S., et al. (2012) Mild Cognitive Impairment: Disparity of Incidence and Prevalence Estimates. Alzheimer’s &amp; Dementia: The Journal of the Alzheimer’s Association, 8, 14-21.  
&lt;br&gt;https://doi.org/10.1016/j.jalz.2011.01.002</mixed-citation></ref><ref id="hanspub.44846-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Nie, H., Xu, Y., Liu, B., et al. (2011) The Prevalence of Mild Cognitive Impairment about Elderly Population in China: A Meta-Analysis. International Journal of Geriatric Psychiatry, 26, 558-563. &lt;br&gt;https://doi.org/10.1002/gps.2579</mixed-citation></ref><ref id="hanspub.44846-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Van de Rest, O., Geleijnse, J.M., Kok, F.J., et al. (2008) Effect of Fish Oil on Cognitive Performance in Older Subjects: A Randomized, Controlled Trial. Neurology, 71, 430-438. &lt;br&gt;https://doi.org/10.1212/01.wnl.0000324268.45138.86</mixed-citation></ref><ref id="hanspub.44846-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">中国痴呆与认知障碍诊治指南写作组, 杜怡峰, 吕佩源, 等. 2018中国痴呆与认知障碍诊治指南(五): 轻度认知障碍的诊断与治疗[J]. 中华医学杂志, 2018, 98(17): 1294-1301.</mixed-citation></ref><ref id="hanspub.44846-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Petersen, R.C., Smith, G.E., Waring, S.C., et al. (1999) Mild Cognitive Impairment: Clinical Characterization and Outcome. Archives of Neurology, 56, 303-308. &lt;br&gt;https://doi.org/10.1001/archneur.56.3.303</mixed-citation></ref><ref id="hanspub.44846-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Rondanelli, M., Opizzi, A., Faliva, M., et al. (2013) Effects of a Diet Integration with an Oily Emulsion of DHA-Phospholipids Containing Melatonin and Tryptophan in Elderly Patients Suffering from Mild Cognitive Impairment. Nutritional Neuroscience, 15, 46-54. &lt;br&gt;https://doi.org/10.1179/1476830511Y.0000000032</mixed-citation></ref><ref id="hanspub.44846-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gauthier, S., Reisberg, B., Zaudig, M., et al. (2006) Mild Cognitive Impairment. The Lancet (London, England), 367, 1262-1270. &lt;br&gt;https://doi.org/10.1016/S0140-6736(06)68542-5</mixed-citation></ref><ref id="hanspub.44846-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Beydoun, M.A., Kaufman, J.S., Satia, J.A., et al. (2007) Plasma n-3 Fatty Acids and the Risk of Cognitive Decline in Older Adults: The Atherosclerosis Risk in Communities Study. The American Journal of Clinical Nutrition, 85, 1103-1111. &lt;br&gt;https://doi.org/10.1093/ajcn/85.4.1103</mixed-citation></ref><ref id="hanspub.44846-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Bo, Y., Zhang, X., Wang, Y., et al. (2017) The n-3 Polyunsaturated Fatty Acids Supplementation Improved the Cognitive Function in the Chinese Elderly with Mild Cognitive Impairment: A Double-Blind Randomized Controlled Trial. Nutrients, 9, 54. &lt;br&gt;https://doi.org/10.3390/nu9010054</mixed-citation></ref><ref id="hanspub.44846-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Lee, L.K., Shahar, S., Chin, A.V., et al. (2013) Docosahexaenoic Acid-Concentrated Fish Oil Supplementation in Subjects with Mild Cognitive Impairment (MCI): A 12-Month Randomised, Double-Blind, Placebo-Controlled Trial. Psychopharmacology (Berl), 225, 605-612. &lt;br&gt;https://doi.org/10.1007/s00213-012-2848-0</mixed-citation></ref><ref id="hanspub.44846-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Sinn, N., Milte, C.M., Street, S.J., et al. (2012) Effects of n-3 Fatty Acids, EPA v. DHA, on Depressive Symptoms, Quality of Life, Memory and Executive Function in Older Adults with Mild Cognitive Impairment: A 6-Month Randomised Controlled Trial. British Journal of Nutrition, 107, 1682-1693. &lt;br&gt;https://doi.org/10.1017/S0007114511004788</mixed-citation></ref><ref id="hanspub.44846-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chiu, C.C., Su, K.P., Cheng, T.C., et al. (2008) The Effects of Omega-3 Fatty Acids Monotherapy in Alzheimer’s Disease and Mild Cognitive Impairment: A Preliminary Randomized Double-Blind Placebo-Controlled Study. Progress in Neuro-Psychopharmacology &amp; Biological Psychiatry, 32, 1538-1544. &lt;br&gt;https://doi.org/10.1016/j.pnpbp.2008.05.015</mixed-citation></ref><ref id="hanspub.44846-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, X.W., Hou, W.S., Li, M., et al. (2016) Omega-3 Fatty Acids and Risk of Cognitive Decline in the Elderly: A Meta-Analysis of Randomized Controlled Trials. Aging Clinical and Experimental Research, 28, 165-166.  
&lt;br&gt;https://doi.org/10.1007/s40520-015-0381-9</mixed-citation></ref><ref id="hanspub.44846-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Cederholm, T., Salem, N. and Palmblad, J. (2013) ω-3 Fatty Acids in the Prevention of Cognitive Decline in Humans. Advances in Nutrition (Bethesda, Md), 4, 672-676. &lt;br&gt;https://doi.org/10.3945/an.113.004556</mixed-citation></ref><ref id="hanspub.44846-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Cutuli, D., De Bartolo, P., Caporali, P., et al. (2014) n-3 Polyunsaturated Fatty Acids Supplementation Enhances Hippocampal Functionality in Aged Mice. Frontiers in Aging Neuroscience, 6, 220.  
&lt;br&gt;https://doi.org/10.3389/fnagi.2014.00220</mixed-citation></ref><ref id="hanspub.44846-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Wong, A.T., Chan, D.C., Barrett, P.H., et al. (2013) Supplementation with n3 Fatty Acid Ethyl Esters Increases Large and Small Artery Elasticity in Obese Adults on a Weight Loss Diet. The Journal of Nutrition, 143, 437-441.  
&lt;br&gt;https://doi.org/10.3945/jn.112.169359</mixed-citation></ref></ref-list></back></article>